Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 for Recurrent C. difficile Infection
NCT04729790Phase 2Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Microbiome Therapeutics
01
Overview
A Phase 2 trial of PRIM-DJ2727 in Clostridioides difficile infection (CDI), sponsored by UTHealth Houston. Planned start Jan 2020; status: withdrawn.
02
Drugs
PRIM-DJ2727
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT04729790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729790.